Immune-mediated acute neuropathies: an immunological analysis of patients hospitalized for Guillain-Barré syndrome in the years 2020-2021 at a university hospital in Vitória, ES, Brazil
DOI:
https://doi.org/10.47456/rbps.v24i3.38987Keywords:
Guillain-Barré syndrome, Diagnostic techniques neurological, Patient acuityAbstract
Introduction:
When analyzing the increase in cases of Guillain-Barré Syndrome (GBS) admitted at a university hospital in Vitória, Es, Brazil, it was suggested to implement a simplified laboratory evaluation, widely available and low cost, which would allow the examiner to predict the risk of unfavorable evolution of the patient diagnosed with an Acute Immune-mediated Polyneuropathy. Objectives: Predict the greater severity of the patient with GBS at hospital admission, the unfavorable evolution of motor strength, in addition to the dependence on oxygen therapy, based on the laboratory analysis of the Total Neutrophils/Lymphocytes (NLR) ratio through the complete blood count (CBC). Methods: Patients with GBS and their admission CBC were evaluated. The data obtained was tabulated for statistical analysis with an appropriate small sample test. Results: NLR proved to be relevant and statistically significant as evidence of worse neurological status on patient admission and higher risk of death. Conclusion: There was statistical relevance of using NLR as an easily accessible and interpretable, besides widely available initial tool to contribute with the anamnesis and physical examination, providing more data for the examining doctor and allowing wide knowledge into the severity status of the patient with GBS.
Downloads
References
Kokcu A, Kurtoglu E, Celik H, Tosun M, Malatyalioglu E, Ozdemir AZ. May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer?. Asian Pac J Cancer Prev. 2014;15(22):9781-4.
Ethemoglu O, Calik M. Effect of serum inflammatory markers on the prognosis of adult and pediatric patients with Guillain–Barré syndrome. Neuropsychiatric Disease and Treatment. 2018;14:1255-1260.
Demirci S, Demirci S, Kutluhan S, Koyuncuoglu HR, Yurekli VA. The clinical significance of the neutrophil-tolymphocyte ratio in multiple sclerosis. The International journal of neuroscience. 2015;126(8)1-7.
Gokhan S, Ozhasenekler A, Mansur Durgun H, Akil E, Ustundag M, Orak M. Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack. European review for medical and pharmacological sciences. 2013;17(5):653-657.
Tokgoz S, Kayrak M, Akpinar Z, Seyithanoglu A, Guney F, Yuruten B. Neutrophil lymphocyte ratio as a predictor of stroke. Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association. 2013;22(7):1169-1174.
Geyik S, Bozkurt H, Neyal M, Yigiter R. The Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Guillain-Barré Syndrome Independent of Infection. Medical Science and Discovery. 2016;3(8):305- 11.
Bruck I, Antoniuk SA, Cat R, Spessatto A, Halick SM, Bruyn LRD, et al. Imunoglobulina endovenosa em crianças com síndrome de Guillain-Barré. Arquivos de Neuro- Psiquiatria. 2000;58:1081-91.
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain- Barre syndrome. Lancet. 2021 Mar 27;397(10280):1214- 1228.
De-Lucca MET; Maffini JF; Grassi MG; Stadler- Junior M; Bezerra VN; João PRD. Síndrome de Guillain- Barré na pediatria: revisão de literatura. Resid Pediatr. 2020;0(0):523.
Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Evidence-Based Guidelines Diagnosis and management of Guillain–Barré Syndrome in ten steps. Rev Neurocienc. 2021;29:1-52.
Ozdemir HH. Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain- Barré syndrome. Arq Neuropsiquiatr. 2016;74(9):718-722.
Yuki N, Chan AC, Wong AHY, Inoue T, Yokai M, Kurihara T, Devaux JJ, Wilder-Smith E. Acute painful autoimmune neuropathy: A variant of Guillain-Barré syndrome. Muscle Nerve. 2018 Feb;57(2):320-324. doi: 10.1002/mus.25738. Epub 2017 Jul 24. PMID: 28667708
Khanmohammadi S, Malekpour M, Jabbari P, Rezaei N. Genetic basis of Guillain-Barre syndrome. J Neuroimmunol. 2021 Sep 15;358:577651. doi: 10.1016/j. jneuroim.2021.577651. Epub 2021 Jul 1. PMID: 34246981
Querol L, Lleixà C. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP. Neurotherapeutics. 2021 Oct;18(4):2222-2235. doi: 10.1007/s13311-021-01117-3. Epub 2021 Sep 21. PMID: 34549385; PMCID: PMC8455117.
Leonhard SE, Cornblath DR, Endtz HP, Sejvar JJ, Jacobs BC. Guillain-Barré syndrome in times of pandemics. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1027- 1029. doi: 10.1136/jnnp-2020-324230. Epub 2020 Jul 30. PMID: 32732383; PMCID: PMC7509514.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
